Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:affiliatedWith |
monoclonal antibodies
cytotoxic agents |
| gptkbp:approvedBy |
gptkb:FDA
2013 |
| gptkbp:ATCCode |
L01XC14
|
| gptkbp:biosimilar |
no
|
| gptkbp:brand |
gptkb:ado-trastuzumab_emtansine
|
| gptkbp:CASNumber |
1018448-65-1
|
| gptkbp:chemicalClass |
gptkb:monoclonal_antibody
|
| gptkbp:contains |
gptkb:DM1_(emtansine)
gptkb:trastuzumab |
| gptkbp:developedBy |
gptkb:Genentech
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kadcyla
|
| gptkbp:indication |
early breast cancer
metastatic breast cancer |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Roche
|
| gptkbp:mechanismOfAction |
gptkb:monoclonal_antibody
|
| gptkbp:pregnancyCategory |
gptkb:C_(Australia)
D (US) |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
fatigue thrombocytopenia liver toxicity |
| gptkbp:target |
HER2-positive cancer
|
| gptkbp:UNII |
P8I9DV1DLU
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:Genentech
|
| gptkbp:bfsLayer |
5
|